Feline esophagus is most commonly associated with which of the following conditions?
A 25-year-old woman develops nausea, vomiting, and abdominal pain. On examination, she has tender hepatomegaly and ascites. She was recently started on oral contraceptives. What is the most likely clinical diagnosis?
Which one of the following treatments is effective in primary biliary cirrhosis?
Which of the following is the first-line therapy for fulminant ulcerative colitis (UC)?
Hyper-pigmented skin with xanthelasma and xanthomas suggests the possibility of which diagnosis?
What is the most common cause of lower gastrointestinal bleeding in adults?
A patient with jaundice is given Vitamin K, but their Prothrombin Time (PT) remains unchanged. What is the probable cause?
A 55-year-old male patient was diagnosed with chronic hepatitis C and responded to interferon treatment. After one year of follow-up, he experienced a relapse of the disease. Which of the following would be the next most appropriate choice?
Which part of the esophagus is mainly affected in scleroderma?
Which is a feature of osmotic diarrhea?
Explanation: **Explanation:** The term **"Feline Esophagus"** (also known as esophageal shingling or transient esophageal rings) refers to the endoscopic appearance of multiple, fine, concentric mucosal rings that resemble the normal anatomy of a cat's esophagus. **1. Why GERD is the correct answer:** While historically debated, current medical literature and standard textbooks (including Harrison’s) associate the classic "feline esophagus" primarily with **Gastroesophageal Reflux Disease (GERD)**. These rings are transient and occur due to the contraction of the *muscularis mucosae* in response to acid irritation [1]. They typically disappear upon esophageal insufflation during endoscopy. **2. Analysis of Incorrect Options:** * **Option A: Eosinophilic Esophagitis (EoE):** This is the most common distractor. EoE is characterized by **fixed** concentric rings (often called "trachealization" of the esophagus). Unlike the transient feline esophagus of GERD, these rings are permanent and do not disappear with air insufflation. * **Option C & D: Radiation Esophagitis and Carcinoma:** These conditions typically present with strictures, ulcerations, or irregular masses rather than the rhythmic, concentric, transient rings seen in feline esophagus. **3. Clinical Pearls for NEET-PG:** * **Feline Esophagus:** Transient rings, associated with **GERD** [1]. * **Trachealization/Ringed Esophagus:** Fixed rings, associated with **Eosinophilic Esophagitis**. * **Endoscopic Triad of EoE:** Fixed rings, linear furrows, and white exudates (microabscesses). * **Key Distinction:** If the question mentions rings that **disappear with insufflation**, think GERD. If they are **fixed/permanent**, think EoE.
Explanation: ### Explanation **Correct Answer: A. Budd-Chiari Syndrome** **Medical Concept:** Budd-Chiari Syndrome (BCS) is caused by the obstruction of hepatic venous outflow at any level from the small hepatic veins to the junction of the inferior vena cava and the right atrium. This leads to increased intrahepatic pressure, centrilobular necrosis, and liver dysfunction. In this clinical vignette, the patient presents with the classic **triad of Budd-Chiari Syndrome**: 1. **Abdominal pain** 2. **Ascites** 3. **Tender hepatomegaly** The most significant risk factor mentioned is the recent start of **oral contraceptives (OCPs)**. OCPs induce a hypercoagulable state, which is a leading cause of hepatic vein thrombosis in young women [1]. --- **Why Incorrect Options are Wrong:** * **B. Acute Viral Hepatitis:** While it presents with nausea, vomiting, and tender hepatomegaly, it rarely causes rapid-onset **ascites** unless there is acute liver failure. The specific association with OCPs points more strongly toward a vascular event. * **C. Portal Hypertension:** This is a clinical *consequence* of various diseases (including BCS), not a primary diagnosis. In an acute setting with tender hepatomegaly, the underlying cause of the hypertension must be identified. * **D. Acute Cholecystitis:** This typically presents with RUQ pain (Murphy’s sign) and fever, but it does not cause generalized ascites or diffuse hepatomegaly. --- **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause (Global):** Thrombosis due to hypercoagulable states (e.g., Polycythemia Vera, Factor V Leiden, OCP use). * **Most common cause (India):** Membranous webs in the Inferior Vena Cava (IVC). * **Investigation of Choice:** **Doppler Ultrasound** (initial); **Venography** (Gold Standard). * **Imaging Sign:** "Caudate lobe hypertrophy" on CT/MRI (as its venous drainage directly enters the IVC, bypassing the hepatic veins). * **Biopsy:** Shows "Nutmeg liver" (centrilobular congestion) [1].
Explanation: **Explanation:** **Primary Biliary Cholangitis (PBC)**, formerly known as Primary Biliary Cirrhosis, is a chronic autoimmune cholestatic liver disease characterized by the T-cell-mediated destruction of small intrahepatic bile ducts [1]. **Why Ursodeoxycholic Acid (UDCA) is the Correct Choice:** UDCA is the **first-line treatment** and the only FDA-approved drug proven to slow disease progression in PBC. It works by: * **Choleretic effect:** Increasing the secretion of bile. * **Cytoprotection:** Replacing endogenous toxic hydrophobic bile acids with hydrophilic, non-toxic UDCA, thereby protecting hepatocytes and cholangiocytes from injury. * **Immunomodulation:** Reducing the expression of MHC molecules on bile duct epithelial cells. Early initiation of UDCA improves biochemical markers (ALP, Bilirubin) and significantly delays the need for liver transplantation. **Why Other Options are Incorrect:** * **Prednisolone:** While PBC is autoimmune, corticosteroids do not significantly alter the long-term course and are generally avoided due to the high risk of accelerating **osteoporosis**, a common complication in PBC patients [1]. * **Interferon α-2B:** This is used for viral hepatitis (B and C) and has no role in the management of PBC. * **D-Penicillamine:** Historically trialed for its copper-chelating and anti-fibrotic properties, it was found to be **ineffective** and associated with significant toxicity in PBC patients. **NEET-PG High-Yield Pearls:** * **Classic Presentation:** Middle-aged female with fatigue and **pruritus** (often the earliest symptom) [1]. * **Diagnostic Marker:** **Anti-Mitochondrial Antibody (AMA)** is highly specific (>95%) [1]. * **Biochemical Hallmark:** Disproportionate rise in **Alkaline Phosphatase (ALP)** and GGT [1]. * **Associated Conditions:** Sjögren’s syndrome, Hashimoto’s thyroiditis, and Celiac disease [1]. * **Second-line Treatment:** **Obeticholic acid** (FXR agonist) is used for patients who do not respond to UDCA.
Explanation: **Explanation:** **Fulminant Ulcerative Colitis (UC)** is a medical emergency characterized by >10 stools per day, continuous bleeding, systemic toxicity (fever, tachycardia), and colonic dilation. **1. Why Steroids are the Correct Choice:** Intravenous (IV) corticosteroids (e.g., **Hydrocortisone 100 mg TID or Methylprednisolone 60 mg daily**) are the **first-line therapy** for inducing remission in acute severe or fulminant UC [1]. They work rapidly to suppress the massive inflammatory surge. Approximately 60–70% of patients respond to steroids within 3–5 days. **2. Why Other Options are Incorrect:** * **Cyclosporine (Option A):** This is a "rescue therapy." It is indicated only if the patient fails to respond to IV steroids after 3–5 days. It is not the initial first-line choice. * **Sulfasalazine (Option B):** 5-ASA compounds are effective for mild-to-moderate UC and maintenance therapy [1]. They have no role in fulminant UC as they are too weak and can paradoxically worsen diarrhea in acute phases. * **Methotrexate (Option C):** While used in Crohn’s disease, it has no proven efficacy in inducing or maintaining remission in Ulcerative Colitis. **3. NEET-PG High-Yield Pearls:** * **The "Rule of 3":** Assess steroid response by day 3. If the patient has >8 stools/day or a CRP >45 mg/L, they are unlikely to respond and need rescue therapy (Infliximab or Cyclosporine) or surgery. * **Toxic Megacolon:** A dreaded complication of fulminant UC. Diagnosis is clinical + X-ray (transverse colon diameter **>6 cm**). * **Avoid:** Antidiarrheals (Loperamide) and Opioids in fulminant UC as they can precipitate toxic megacolon. * **Surgery:** Total proctocolectomy with Ileal Pouch-Anal Anastomosis (IPAA) is the definitive curative procedure [2].
Explanation: **Explanation:** The clinical triad of **hyperpigmentation, xanthelasma, and xanthomas** in the context of chronic cholestasis is a classic presentation of **Primary Biliary Cholangitis (PBC)** [1], formerly known as Primary Biliary Cirrhosis. 1. **Why Primary Biliary Cholangitis (PBC) is correct:** * **Hyperpigmentation:** Chronic cholestasis leads to increased melanin deposition in the skin (mechanism linked to increased melanocyte-stimulating hormone or opioid peptides). * **Xanthelasma/Xanthomas:** PBC is characterized by significant **hyperlipidemia** (specifically high cholesterol). Impaired bile acid excretion leads to the accumulation of cholesterol, which deposits in the skin as xanthelasma (around the eyes) and plane or tuberous xanthomas (over joints/palms) [1]. * **Pruritus:** This is often the earliest symptom, preceding jaundice [1]. 2. **Why other options are incorrect:** * **Primary Sclerosing Cholangitis (PSC):** While it causes cholestasis, it is more commonly associated with **Ulcerative Colitis** and "beading" of bile ducts on MRCP [2]. It rarely presents with the prominent hyperlipidemia/xanthomas seen in PBC. * **Amyloidosis:** Can cause hepatomegaly and skin changes (like "pinch purpura" or waxy papules), but it does not typically cause the specific lipid-related deposits seen in cholestatic liver disease. * **Tuberculosis:** While it can cause systemic symptoms and skin lesions (Lupus vulgaris), it does not present with the metabolic/cholestatic features of xanthomas. **NEET-PG High-Yield Pearls for PBC:** * **Demographics:** Classically affects middle-aged women ("Rule of Ms": **M**iddle-aged **M**others) [2]. * **Marker:** **Anti-Mitochondrial Antibody (AMA)** is the most specific marker (>95%) [2]. * **Pathology:** Non-suppurative destructive cholangitis of small intrahepatic bile ducts (**Florid duct lesion**) [2]. * **Treatment:** **Ursodeoxycholic acid (UDCA)** is the first-line treatment to slow progression. * **Association:** Strongly associated with other autoimmune diseases like Sjögren’s syndrome and Hashimoto’s thyroiditis [2].
Explanation: **Explanation:** **Correct Answer: A. Diverticulosis (Diverticular Disease)** *Note: While the option says "Diverticulitis," in clinical practice and exams, **Diverticulosis** is the most common cause of brisk, painless lower gastrointestinal bleeding (LGIB) in adults, accounting for approximately 30–50% of cases. The bleeding occurs because the vasa recta (nutrient arteries) become stretched over the dome of the diverticulum, leading to eccentric thickening and eventual rupture into the colonic lumen.* [1] **Analysis of Incorrect Options:** * **B. Ulcerative Colitis:** While inflammatory bowel disease (IBD) frequently causes bloody diarrhea, it is a less common cause of massive or acute LGIB compared to diverticular disease. [2] * **C. Angiodysplasia:** These are small vascular malformations (ectasias). While they are a common cause of chronic or occult bleeding in the elderly (especially in the right colon), they account for only about 5–10% of acute LGIB cases. * **D. Colorectal Cancer:** Malignancies typically present with chronic, low-grade occult bleeding (leading to iron deficiency anemia) rather than acute, massive hematochezia. [2] **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of LGIB in adults:** Diverticulosis. * **Most common cause of LGIB in children:** Meckel’s Diverticulum. * **Anatomical Fact:** Although diverticula are more common on the left side (sigmoid colon), diverticular **bleeding** more frequently originates from the **right colon**. * **Clinical Presentation:** Diverticular bleeding is typically **painless** and sudden, whereas bleeding from diverticulitis is rare (inflammation usually obliterates the vessel). * **Management:** Most cases (75%) of diverticular bleeding resolve spontaneously with conservative management. [1]
Explanation: **Explanation:** The correct answer is **Cirrhosis**. This question tests the clinical application of the **Koller Test**, which differentiates between obstructive jaundice and parenchymal liver disease. **1. Why Cirrhosis is correct:** Prothrombin Time (PT) depends on the synthesis of clotting factors (II, VII, IX, and X) by the liver. This process requires **Vitamin K** as a cofactor. In **Cirrhosis**, there is extensive damage to the hepatocytes (liver cells). Even if Vitamin K is supplemented, the "factory" (the liver) is too damaged to utilize it to synthesize clotting factors [1]. Therefore, the PT remains prolonged and unchanged. **2. Why the other options are incorrect:** * **Obstructive Jaundice:** In this condition, bile flow is blocked, leading to poor absorption of fat-soluble vitamins (A, D, E, K). The liver cells are initially healthy but lack the raw material (Vitamin K). When Vitamin K is given parenterally, the healthy liver quickly uses it, and the **PT corrects** within 24–48 hours [1]. * **Hemolytic Jaundice:** This is a pre-hepatic condition where jaundice is caused by excessive RBC breakdown. Liver function and Vitamin K absorption are typically normal; thus, PT is usually not prolonged. * **Pre-renal Failure:** This relates to kidney perfusion and does not directly affect the Vitamin K-dependent clotting factor synthesis. **Clinical Pearls for NEET-PG:** * **Koller Test:** If PT improves by >30% within 24 hours of Vitamin K injection, it suggests obstructive jaundice. No improvement suggests parenchymal disease (Cirrhosis). * **Factor VII:** Has the shortest half-life (4–6 hours) among clotting factors, making PT the earliest indicator of acute liver injury [1]. * **Albumin vs. PT:** Albumin is a marker of **chronic** liver synthetic function, while PT is a marker of **acute and chronic** synthetic function [1].
Explanation: **Explanation:** The management of Chronic Hepatitis C (HCV) has evolved significantly, but for the purpose of standard medical examinations, the focus remains on the synergistic relationship between **Interferon (IFN)** and **Ribavirin**. [1] **1. Why Option A is Correct:** In patients who relapse after a course of Interferon monotherapy, the standard of care (historically and in classic exam scenarios) is to initiate **Combination Therapy** with **Pegylated Interferon and Ribavirin**. Ribavirin is a nucleoside analog that does not have significant anti-HCV activity as monotherapy but significantly enhances the sustained virologic response (SVR) when added to Interferon by inhibiting viral RNA polymerase and modulating the host immune response. [1] **2. Why the Other Options are Incorrect:** * **Option B (Lamivudine and Interferon):** Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) used for Hepatitis B (HBV) and HIV. It has no efficacy against the HCV virus. * **Option C (Nevirapine and Lamivudine):** This is a combination used in Highly Active Antiretroviral Therapy (HAART) for HIV. Nevirapine is an NNRTI and is not used for hepatitis. * **Option D (Indinavir and Ribavirin):** Indinavir is a Protease Inhibitor used for HIV. While Ribavirin is used for HCV, Indinavir is not an anti-HCV agent. **Clinical Pearls for NEET-PG:** * **Gold Standard Goal:** The primary goal of HCV treatment is **SVR (Sustained Virologic Response)**, defined as undetectable HCV RNA 12–24 weeks after completing therapy. * **Ribavirin Side Effect:** The most high-yield side effect to remember is **dose-dependent hemolytic anemia**. It is also highly **teratogenic** (requires strict contraception). * **Modern Update:** While this question reflects classic teaching, modern real-world practice has shifted to **Direct-Acting Antivirals (DAAs)** like Sofosbuvir and Ledipasvir, which have >95% cure rates. * **Interferon Side Effects:** Often presents as "flu-like symptoms" and neuropsychiatric issues (depression). [1]
Explanation: **Explanation:** The correct answer is **C. Lower third.** **1. Why the Lower Third is affected:** Systemic Sclerosis (Scleroderma) primarily affects **smooth muscle**. The esophagus is anatomically divided by its muscle composition: the upper third consists of skeletal muscle, the middle third is a transition zone, and the **lower two-thirds** consist entirely of smooth muscle. In Scleroderma, vascular damage and fibrosis lead to atrophy of the smooth muscle and dysfunction of the myenteric plexus [1]. This results in: * **Aperistalsis** of the distal (lower) esophagus [1]. * **Incompetence of the Lower Esophageal Sphincter (LES)**, leading to severe Gastroesophageal Reflux Disease (GERD) and potential strictures [1]. **2. Why other options are incorrect:** * **Option A (Upper third):** This segment is composed of **striated (skeletal) muscle**. Diseases affecting this area include Dermatomyositis, Myasthenia Gravis, or Myotonic Dystrophy, rather than Scleroderma [1]. * **Option B (Middle third):** While the middle third contains some smooth muscle and can be partially involved, the pathological hallmark of Scleroderma is most profound in the distal smooth muscle segment and the LES. * **Option D (All the above):** Scleroderma characteristically spares the skeletal muscle of the proximal esophagus. **Clinical Pearls for NEET-PG:** * **CREST Syndrome:** Esophageal dysmotility is the 'E' in CREST [1]. * **Manometry Findings:** Characterized by "Low-amplitude" or absent contractions in the distal esophagus and a "Hypotensive" (low pressure) LES. * **Barrett’s Esophagus:** Due to chronic, severe reflux from a patulous LES, Scleroderma patients are at high risk for Barrett’s and esophageal adenocarcinoma. * **"Glass Pipe" Esophagus:** A radiological description sometimes used for the dilated, aperistaltic esophagus seen on barium swallow.
Explanation: **Explanation:** The core pathophysiology of **osmotic diarrhea** is the presence of non-absorbable, osmotically active solutes in the intestinal lumen. These solutes draw water into the gut to maintain isotonicity, leading to increased stool water [1]. **1. Why Option B is Correct:** Osmotic diarrhea is driven by the ingestion of specific substances (e.g., lactose in lactase deficiency, magnesium salts, or sorbitol) [1]. When a patient is **fasting**, the offending solute is no longer being ingested. Consequently, the osmotic gradient disappears, and the diarrhea **decreases or stops**. This is the classic clinical hallmark that differentiates it from secretory diarrhea [2]. **2. Why the other options are incorrect:** * **Option A (Volume >1 litre):** Large volume stools (>1 L/day) are characteristic of **secretory diarrhea** (e.g., Cholera, VIPoma). Osmotic diarrhea typically results in smaller volumes, usually <1 L/day. * **Option C (Infectious etiology):** Most infectious diarrheas (like *Vibrio cholerae* or Enterotoxigenic *E. coli*) are **secretory** in nature. Osmotic diarrhea is usually due to malabsorption (Lactose intolerance) or laxative abuse [2]. * **Option D (Osmotic gap <50 mmol):** In osmotic diarrhea, the **Stool Osmotic Gap is high (>125 mOsm/kg)** because the measured electrolytes (Na+ and K+) do not account for the total osmolality; the "gap" is filled by the unmeasured non-absorbable solute. A gap <50 mOsm/kg is characteristic of secretory diarrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Formula:** Stool Osmotic Gap = $290 - 2 \times (\text{Stool Na}^+ + \text{Stool K}^+)$. * **Secretory Diarrhea:** Does NOT stop with fasting; Osmotic gap is low (<50). * **Osmotic Diarrhea:** Stops with fasting; Osmotic gap is high (>125); Stool pH is often acidic (due to bacterial fermentation of carbohydrates) [2].
Esophageal Disorders
Practice Questions
Peptic Ulcer Disease
Practice Questions
Inflammatory Bowel Disease
Practice Questions
Irritable Bowel Syndrome
Practice Questions
Malabsorption Syndromes
Practice Questions
Pancreatitis (Acute and Chronic)
Practice Questions
Gastrointestinal Bleeding
Practice Questions
Liver Diseases and Cirrhosis
Practice Questions
Viral Hepatitis
Practice Questions
Biliary Tract Disorders
Practice Questions
Gastrointestinal Motility Disorders
Practice Questions
Gastrointestinal Malignancies
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free